RGH 2716

Drug Profile

RGH 2716

Alternative Names: TDN 345

Latest Information Update: 11 Oct 2000

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Takeda
  • Developer Gedeon Richter
  • Class Anti-ischaemics; Neuroprotectants; Nootropics
  • Mechanism of Action Calcium channel antagonists; Nerve growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cerebral ischaemia; Cognition disorders

Most Recent Events

  • 11 Oct 2000 Discontinued-Preclinical for Cerebral ischaemia in Hungary (Unknown route)
  • 11 Oct 2000 Discontinued-Preclinical for Cognition disorders in Hungary (Unknown route)
  • 12 Jun 2000 Profile reviewed but no significant changes made
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top